Peripheral Artery DiseasePhase 3EUCLIDNCT01732822

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

A Phase 3 study testing Ticagrelor and Clopidogrel in people with Peripheral Artery Disease, run by AstraZeneca at 776 sites in 28 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease. Read more about this study

Who is it for?: Ages 50 to 130 years
Conditions the study is for: Peripheral Artery Disease
What is being tested?: Ticagrelor and Clopidogrel
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 13,885 participants
Where: 776 sitesin 28 countries
Study dates: 4 Dec 2012to 26 Sep 2016
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 50 to 130 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Male and Female patients 50 years old or older Symptomatic peripheral artery disease

Who cannot join

Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation
Patients with known bleeding disorders
Patients with a history of intracranial bleed
Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker

Trial locations and contacts

776 sites in 28 countries.

Country

City, postcode or hospital

776 sites in 28 countries

United States290 sites

Research Site
Albany, New York, 12211
Research Site
Albuquerque, New Mexico, 87108
Research Site
Alexander City, Alabama, 35010
Research Site
Alexandria, Louisiana, 71301
Research Site
Amarillo, Texas, 79106
Research Site
Anaheim, California, 92801
Research Site
Arlington Heights, Illinois, 60005
Research Site
Atlanta, Georgia, 30310
Research Site
Atlanta, Georgia, 30342
Research Site
Atlantis, Florida, 33462
Research Site
Auburn, Alabama, 36830
Research Site
Auburn, Maine, 04210
Research Site
Augusta, Georgia, 30901
Research Site
Austin, Texas, 78705
Research Site
Baltimore, Maryland, 21201
Research Site
Baton Rouge, Louisiana, 70808
Research Site
Belleville, New Jersey, 07109
Research Site
Beltsville, Maryland, 20705
Research Site
Berkeley, California, 94705
Research Site
Beverly Hills, California, 90210
Research Site
Biloxi, Mississippi, 39532
Research Site
Birmingham, Alabama, 35235
Research Site
Birmingham, Alabama, 35294
Research Site
Bossier City, Louisiana, 71111
Research Site
Bradenton, Florida, 34201
Research Site
Brandon, Florida, 33511
Research Site
Bridgeport, Connecticut, 06610
Research Site
Bridgewater, New Jersey, 08807
Research Site
Bristol, Tennessee, 37620
Research Site
Brooklyn, New York, 11215
Research Site
Brooksville, Florida, 34601
Research Site
Camden, New Jersey, 08103
Research Site
Camp Hill, Pennsylvania, 17011
Research Site
Canton, Ohio, 44710
Research Site
Centerville, Ohio, 45459
Research Site
Chapel Hill, North Carolina, 27599-7081
Research Site
Charleston, South Carolina, 29425
Research Site
Charleston, West Virginia, 25304
Research Site
Charlotte, North Carolina, 28204
Research Site
Charlottesville, Virginia, 22908
Research Site
Chicago, Illinois, 60611
Research Site
Chicago, Illinois, 60616
Research Site
Chula Vista, California, 91911-1350
Research Site
Cincinnati, Ohio, 45267-0769
Research Site
Clearwater, Florida, 33756
Research Site
Cleveland, Ohio, 44106
Research Site
Cleveland, Ohio, 44195
Research Site
Columbia, Maryland, 21044
Research Site
Columbia, South Carolina, 29204
Research Site
Concord, North Carolina, 28025
Research Site
Corpus Christi, Texas, 78404
Research Site
Cottonwood, Arizona, 86326
Research Site
Cumming, Georgia, 30041
Research Site
Dallas, Texas, 75216
Research Site
Dayton, Ohio, 45414
Research Site
Daytona Beach, Florida, 32114
Research Site
Daytona Beach, Florida, 32117
Research Site
Doylestown, Pennsylvania, 18901
Research Site
Duluth, Minnesota, 55805
Research Site
Dunmore, Pennsylvania, 18509
Research Site
Easley, South Carolina, 29640
Research Site
East Orange, New Jersey, 07018-1095
Research Site
Eatontown, New Jersey, 07724
Research Site
Edgewood, Kentucky, 41071-3441
Research Site
El Cajon, California, 92020
Research Site
Elkhart, Indiana, 46514
Research Site
Elmer, New Jersey, 08318
Research Site
Erie, Pennsylvania, 16502
Research Site
Erie, Pennsylvania, 16550
Research Site
Fall River, Massachusetts, 02720
Research Site
Falls Church, Virginia, 22042
Research Site
Fargo, North Dakota, 58103
Research Site
Fargo, North Dakota, 58122-0352
Research Site
Flemington, New Jersey, 08822
Research Site
Flint, Michigan, 48503
Research Site
Flint, Michigan, 48532
Research Site
Fort Myers, Florida, 33907
Research Site
Fort Smith, Arkansas, 72901
Research Site
Fort Wayne, Indiana, 46804
Research Site
Fort Wayne, Indiana, 46845
Research Site
Fort Worth, Texas, 76104
Research Site
Fort Worth, Texas, 76117
Research Site
Freehold, New Jersey, 07728
Research Site
Fresno, California, 93721
Research Site
Friendswood, Texas, 77546
Research Site
Gainesville, Florida, 32605
Research Site
Grand Rapids, Michigan, 49503
Research Site
Greenbelt, Maryland, 20770
Research Site
Greensboro, North Carolina, 27401
Research Site
Greenville, South Carolina, 29615
Research Site
Greenwood, South Carolina, 29646
Research Site
Guilford, Connecticut, 06437
Research Site
Hackensack, New Jersey, 07601
Research Site
Haddon Heights, New Jersey, 08035
Research Site
Haverhill, Massachusetts, 01830
Research Site
Hawthorne, New York, 10532
Research Site
Hershey, Pennsylvania, 17033
Research Site
High Point, North Carolina, 27262
Research Site
Hillsboro, Oregon, 97123-4117
Research Site
Hinsdale, Illinois, 60521
Research Site
Houston, Texas, 77030
Research Site
Houston, Texas, 77339
Research Site
Hudson, Florida, 34667
Research Site
Hurst, Texas, 76054
Research Site
Idaho Falls, Idaho, 83404
Research Site
Indianapolis, Indiana, 46237
Research Site
Indianapolis, Indiana, 46260
Research Site
Iowa City, Iowa, 52242
Research Site
Jackson, Mississippi, 39216
Research Site
Jackson, Tennessee, 38301
Research Site
Jacksonville, Florida, 32205
Research Site
Jacksonville, Florida, 32207
Research Site
Jacksonville, Florida, 32209
Research Site
Jacksonville, Florida, 32216
Research Site
Jacksonville, Florida, 32258
Research Site
Johnson City, New York, 13790
Research Site
Jonesboro, Arkansas, 72401
Research Site
Kalamazoo, Michigan, 49008
Research Site
Kalispell, Montana, 59901
Research Site
Kansas City, Missouri, 64111
Research Site
Kettering, Ohio, 45429
Research Site
Killeen, Texas, 76549
Research Site
Knoxville, Tennessee, 37934
Research Site
La Jolla, California, 92093
Research Site
La Mesa, California, 91942
Research Site
Laguna Hills, California, 92653
Research Site
Langhorne, Pennsylvania, 19047
Research Site
Lansing, Michigan, 48910
Research Site
Largo, Florida, 33777
Research Site
Las Vegas, Nevada, 89121
Research Site
Las Vegas, Nevada, 89146
Research Site
Leesburg, Virginia, 20176
Research Site
Lenoir, North Carolina, 28645
Research Site
Lincoln, Nebraska, 68506
Research Site
Lincoln, Nebraska, 68526
Research Site
Linden, New Jersey, 07036
Research Site
Lithonia, Georgia, 30058
Research Site
Little Rock, Arkansas, 72205
Research Site
Liverpool, New York, 13088
Research Site
Long Beach, California, 90822
Research Site
Louisville, Kentucky, 40205
Research Site
Loveland, Colorado, 80538
Research Site
Lubbock, Texas, 79410
Research Site
Lynchburg, Virginia, 24501
Research Site
Macon, Georgia, 31217
Research Site
Madison, Wisconsin, 52713
Research Site
Manassas, Virginia, 20109
Research Site
Manitowoc, Wisconsin, 54220
Research Site
Martinez, Georgia, 30907
Research Site
McAllen, Texas, 78501
Research Site
McAllen, Texas, 78503
Research Site
McKinney, Texas, 75069
Research Site
Memphis, Tennessee, 38104
Research Site
Merrillville, Indiana, 46410
Research Site
Mesa, Arizona, 85206
Research Site
Miami, Florida, 33173
Research Site
Miami, Florida, 33176
Research Site
Midlothian, Virginia, 23114
Research Site
Milwaukee, Wisconsin, 53215
Research Site
Minneapolis, Minnesota, 55407
Research Site
Minneapolis, Minnesota, 55454
Research Site
Minot, North Dakota, 58701
Research Site
Mission Viejo, California, 92691
Research Site
Mobile, Alabama, 36604
Research Site
Mobile, Alabama, 36608
Research Site
Mobile, Alabama, 36617
Research Site
Mooresville, North Carolina, 28117
Research Site
Moreno Valley, California, 92553
Research Site
Mount Clemens, Michigan, 48043
Research Site
Muncie, Indiana, 47303
Research Site
Munster, Indiana, 46321
Research Site
Muskegon, Michigan, 49444
Research Site
Nashville, Tennessee, 37203
Research Site
Nashville, Tennessee, 37232-0700
Research Site
New Brunswick, New Jersey, 08901
Research Site
New York, New York, 10001
Research Site
New York, New York, 10016
Research Site
New York, New York, 10029
Research Site
Newark, Delaware, 19713
Research Site
Newark, Delaware, 19718-0002
Research Site
Newark, New Jersey, 07102
Research Site
Newark, New Jersey, 07103
Research Site
Newport, Pennsylvania, 17074
Research Site
North Las Vegas, Nevada, 89086
Research Site
North Richland Hills, Texas, 76180
Research Site
Northridge, California, 91325-4139
Research Site
Norwalk, Connecticut, 06851
Research Site
Ocala, Florida, 34471
Research Site
Ocean City, New Jersey, 07712
Research Site
Oceanside, California, 92056
Research Site
Odessa, Texas, 79761
Research Site
Ogden, Utah, 84403
Research Site
Oklahoma City, Oklahoma, 73104
Research Site
Oklahoma City, Oklahoma, 73120
Research Site
Orange, California, 92868
Research Site
Orange Park, Florida, 32003
Research Site
Owensboro, Kentucky, 42303
Research Site
Palm Harbor, Florida, 34684
Research Site
Palo Alto, California, 94304-1290
Research Site
Pawtucket, Rhode Island, 02860
Research Site
Pensacola, Florida, 32501
Research Site
Philadelphia, Pennsylvania, 19102
Research Site
Philadelphia, Pennsylvania, 19104
Research Site
Philadelphia, Pennsylvania, 19106
Research Site
Philadelphia, Pennsylvania, 19115
Research Site
Philadelphia, Pennsylvania, 19140
Research Site
Philadelphia, Pennsylvania, 19153
Research Site
Phoenix, Arizona, 85006
Research Site
Phoenix, Arizona, 85012
Research Site
Plantation, Florida, 33324
Research Site
Poughkeepsie, New York, 12601
Research Site
Puyallup, Washington, 98372
Research Site
Raleigh, North Carolina, 27609
Research Site
Raleigh, North Carolina, 27610
Research Site
Rapid City, South Dakota, 57701
Research Site
Rock Island, Illinois, 61201
Research Site
Rockford, Illinois, 61108
Research Site
Rocky Mount, North Carolina, 27804
Research Site
Round Rock, Texas, 78681
Research Site
Sacramento, California, 95816
Research Site
Sacramento, California, 95817
Research Site
Safety Harbor, Florida, 34695
Research Site
Saint Cloud, Minnesota, 56303
Research Site
Salt Lake City, Utah, 84132
Research Site
San Diego, California, 92114
Research Site
San Diego, California, 92120
Research Site
San Francisco, California, 94143-0222
Research Site
Sarasota, Florida, 34239
Research Site
Saratoga Springs, New York, 12866
Research Site
Savannah, Georgia, 31404
Research Site
Sayre, Pennsylvania, 18840
Research Site
Scottsdale, Arizona, 85260
Research Site
Sellersville, Pennsylvania, 18960
Research Site
Sewell, New Jersey, 08080
Research Site
Shreveport, Louisiana, 71103
Research Site
Shreveport, Louisiana, 71105
Research Site
South Charleston, West Virginia, 25309
Research Site
Spokane, Washington, 99204
Research Site
Spokane, Washington, 99210
Research Site
Springfield, Ohio, 45504
Research Site
St Louis, Missouri, 63104
Research Site
St Louis, Missouri, 63128
Research Site
St Louis, Missouri, 63136
Research Site
St Louis, Missouri, 63141
Research Site
St. Petersburg, Florida, 33701
Research Site
St. Petersburg, Florida, 33709
Research Site
Stamford, Connecticut, 06905
Research Site
Statesville, North Carolina, 28625
Research Site
Stockton, California, 95210
Research Site
Stuart, Florida, 34996
Research Site
Summit, New Jersey, 07902
Research Site
Tacoma, Washington, 98405
Research Site
Tallahassee, Florida, 32308
Research Site
Tampa, Florida, 33606
Research Site
Tampa, Florida, 33613
Research Site
The Bronx, New York, 10461
Research Site
The Bronx, New York, 10469
Research Site
Toledo, Ohio, 43606
Research Site
Torrance, California, 90505-5073
Research Site
Torrance, California, 90509
Research Site
Trinity, Florida, 34655
Research Site
Troy, New York, 12180
Research Site
Trumbull, Connecticut, 06611
Research Site
Tucker, Georgia, 30084
Research Site
Tupelo, Mississippi, 38801
Research Site
Tyler, Texas, 75701
Research Site
Tyler, Texas, 75708
Research Site
Valparaiso, Indiana, 46383
Research Site
Vero Beach, Florida, 32960
Research Site
Victoria, Texas, 77901
Research Site
Voorhees Township, New Jersey, 08043
Research Site
Washington D.C., District of Columbia, 20422
Research Site
Wausau, Wisconsin, 54401
Research Site
Webster, Texas, 77598
Research Site
Wellington, Florida, 33449
Research Site
West Des Moines, Iowa, 50266
Research Site
West Orange, New Jersey, 07052
Research Site
West Palm Beach, Florida, 33401
Research Site
Williamsville, New York, 14221
Research Site
Wilmington, Delaware, 19803
Research Site
Wilmington, North Carolina, 28401
Research Site
Winchester, Virginia, 22601
Research Site
Winston-Salem, North Carolina, 27103
Research Site
Worcester, Massachusetts, 01655
Research Site
Wormleysburg, Pennsylvania, 17043
Research Site
Wyomissing, Pennsylvania, 19610
Research Site
Yonkers, New York, 10701
Research Site
York, Pennsylvania, 17403
Research Site
Youngstown, Ohio, 44501
Research Site
Zanesville, Ohio, 43701

Other trials in United States

Japan38 sites

Research Site
Asahi-shi, 289-2511
Research Site
Beppu-shi, 874-0011
Research Site
Fukuoka, 810-0001
Research Site
Hamada-shi, 697-8511
Research Site
Himeji-shi, 671-1227
Research Site
Imabari, 799-1592
Research Site
Kasuga-shi, 816-0864
Research Site
Kishiwada-shi, 596-8522
Research Site
Kobe, 651-0053
Research Site
Koriyama-shi, 963-8052
Research Site
Kyoto, 607-8062
Research Site
Matsubara-shi, 580-0032
Research Site
Matsuyama, 790-8524
Research Site
Matsuyama, 791-8026
Research Site
Meguro-ku, 152-8902
Research Site
Mito, 310-0011
Research Site
Miura-gun, 240-0116
Research Site
Ogori-shi, 838-0141
Research Site
Ōita, 870-0192
Research Site
Sakaide-shi, 762-0007
Research Site
Sapporo, 060-0031
Research Site
Sapporo, 060-0033
Research Site
Sapporo, 063-0005
Research Site
Sapporo, 065-0027
Research Site
Shinjuku-ku, 162-8655
Research Site
Shizuoka, 420-0853
Research Site
Suwa-shi, 392-8510
Research Site
tabashi City, 173-8610
Research Site
Toyonaka-shi, 560-8565
Research Site
Tsu, 514-8507
Research Site
Uji-shi, 611-0041
Research Site
Wakayama, 640-8158
Research Site
Yamagata, 990-8545
Research Site
Yatsushiro-shi, 866-8533
Research Site
Yokohama, 231-0023
Research Site
Yokohama, 234-8503
Research Site
Yokohama, 236-0004
Research Site
Yokosuka-shi, 238-8567

Other trials in Japan

Russia31 sites

Research Site
Arkhangelsk, 163001
Research Site
Chelyabinsk, 454021
Research Site
Gatchina, 188300
Research Site
Kazan', 420043
Research Site
Kazan', 420101
Research Site
Moscow, 117292
Research Site
Moscow, 117630
Research Site
Moscow, 127018
Research Site
Moscow, 129090
Research Site
Nizhny Novgorod, 603018
Research Site
Novosibirsk, 630055
Research Site
Perm, 614000
Research Site
Perm, 614107
Research Site
Perm, 6144090
Research Site
Rostov-on-Don, 344022
Research Site
Saint Petersburg, 191015
Research Site
Saint Petersburg, 192242
Research Site
Saint Petersburg, 194354
Research Site
Saint Petersburg, 195271
Research Site
Saint Petersburg, 197022
Research Site
Saint Petersburg, 197374
Research Site
Saint Petersburg, 197706
Research Site
Saint Petersburg, 198260
Research Site
Saint Petersburg
Research Site
Saratov, 410028
Research Site
Tomsk, 234012
Research Site
Tomsk, 634012
Research Site
Tver', 170036
Research Site
Vladikavkaz, 362007
Research Site
Yekaterinburg, 620039
Research Site
Yekaterinburg, 620149

Other trials in Russia

Spain27 sites

Research Site
A Coruña, 15006
Research Site
Albacete, 02006
Research Site
Alcorcón, 28922
Research Site
Alicante, 03010
Research Site
Badalona (Barcelona), 08916
Research Site
Badalona(Barcelona), 08916
Research Site
Barcelona, 08023
Research Site
Barcelona, 08025
Research Site
Boadilla del Monte, 28660
Research Site
Getafe, 29905
Research Site
Granada, 18012
Research Site
Hospitalet de Llobregat(Barcel, 08907
Research Site
Huelva, 21005
Research Site
Lleida, 25198
Research Site
Madrid, 28007
Research Site
Madrid, 28028
Research Site
Madrid, 28040
Research Site
Madrid, 28046
Research Site
Málaga, 29010
Research Site
Mallorca, 07120
Research Site
Manises, 46940
Research Site
Oviedo, 33006
Research Site
Sabadell, 08208
Research Site
Tarragona, 43005
Research Site
Toledo, 45004
Research Site
Valencia, 46014
Research Site
Valencia, 46026

Other trials in Spain

Canada26 sites

Research Site
Brampton, Ontario, L6Z 4N5
Research Site
Bridgewater, Nova Scotia, B4V 3N2
Research Site
Brossard, Quebec, J4Z 2K9
Research Site
Chicoutimi, G7H 5H6
Research Site
Gatineau, Quebec, J8Y 6S8
Research Site
Greenfield Park, Quebec, J4V 2G8
Research Site
Guelph, Ontario, N1H 1B1
Research Site
London, Ontario, N6A 5W9
Research Site
Montreal, Quebec, H1M 1B1
Research Site
Montreal, Quebec, H1T 1C8
Research Site
Montreal, Quebec, H1T 3Y7
Research Site
North York, Ontario, M3M 3E5
Research Site
Ottawa, Ontario, K1K 4L2
Research Site
Ottawa, Ontario, K1Y 4E9
Research Site
Québec, Quebec, G1G 3Y8
Research Site
Québec, Quebec, G1L 3L5
Research Site
Québec, Quebec, G1N 4V3
Research Site
Québec, Quebec, G3K 2P8
Research Site
Saint-Charles-Borromée, Quebec, J6E 6J2
Research Site
Smiths Falls, Ontario, K7A 4W8
Research Site
St. John's, Newfoundland and Labrador, A1A 3R5
Research Site
St. John's, Newfoundland and Labrador, A1C 5B8
Research Site
Toronto, Ontario, M5B 1W8
Research Site
Trois-Rivières, Quebec, G8Z 3R9
Research Site
Vancouver, British Columbia, V5Z 1M9
Research Site
Winnipeg, Manitoba, R2H 2A6

Other trials in Canada

Brazil25 sites

Research Site
Belo Horizonte, 30110-100
Research Site
Belo Horizonte, 30110070
Research Site
Belo Horizonte, 30150-240
Research Site
Belo Horizonte, 30190-130
Research Site
Brasília, 70710-905
Research Site
Campinas, 13010-001
Research Site
Campinas, 13060 904
Research Site
Canoas, 92425-900
Research Site
Curitiba, 80010-030
Research Site
Curitiba, 80730-150
Research Site
Juiz de Fora, 36010 570
Research Site
Porto Alegre, 90035903
Research Site
Porto Alegre, 90610-000
Research Site
Porto Alegre, 90620-001
Research Site
Rio de Janeiro, 20551-030
Research Site
Salvador, 40140-110
Research Site
Salvador, 41810-010
Research Site
Santo André, 09060-650
Research Site
São Bernardo do Campo, 09715090
Research Site
São José do Rio Preto, 15015210
Research Site
São José do Rio Preto, 15090-000
Research Site
São Paulo, 04039-000
Research Site
São Paulo, 05017-00
Research Site
Tatuí, 18270-170
Research Site
Uberlândia, 38400-368

Other trials in Brazil

France25 sites

Research Site
Amiens, 80054
Research Site
Bayonne, 64100
Research Site
Bordeaux, 33075
Research Site
Brest, 29609
Research Site
Caen, F-14033
Research Site
Castelnau-le-Lez, F-34170
Research Site
Dijon, 21079
Research Site
La Tronche, 38700
Research Site
Le Chesnay, 78157
Research Site
Le Coudray, 28630
Research Site
Limoges, 87042
Research Site
Montpellier, 34295
Research Site
Nantes, 44277
Research Site
Paris, 75651
Research Site
Paris, 75674
Research Site
Paris, 75908
Research Site
Pessac, 33604
Research Site
Rambouillet, 78120
Research Site
Saint-Priest-en-Jarez, 42270
Research Site
Strasbourg, 67091
Research Site
Thionville, 57100
Research Site
Toulouse, 31059
Research Site
Toulouse, 31076
Research Site
Tours, 37044
Research Site
Vandœuvre-lès-Nancy, 54511

Other trials in France

Germany25 sites

Research Site
Berlin, 10713
Research Site
Berlin, 10787
Research Site
Berlin, 12203
Research Site
Dresden, 01099
Research Site
Dresden, 01219
Research Site
Dresden, 01307
Research Site
Dresden, 1067
Research Site
Erlangen, 91054
Research Site
Ettlingen, 76275
Research Site
Frankfurt am Main, 60590
Research Site
Hamburg, 20099
Research Site
Hamburg, 20246
Research Site
Hamburg, 22041
Research Site
Hamburg, 22559
Research Site
Heidelberg, 69120
Research Site
Kaiserslautern, 67657
Research Site
Leipzig, 04103
Research Site
Mainz, 55131
Research Site
Merseburg, 06217
Research Site
München, 80331
Research Site
München, 80336
Research Site
München, 80638
Research Site
Riesa, 01587
Research Site
Tübingen, 72076
Research Site
Wesel, 46483

Other trials in Germany

China24 sites

Research Site
Beijing, 100029
Research Site
Beijing, 100038
Research Site
Beijing, 100191
Research Site
Beijing, 100853
Research Site
Changsha, 410008
Research Site
Changsha, 410013
Research Site
Fuzhou, 350025
Research Site
Haerbin, 150001
Research Site
Hubei, 430022
Research Site
Nanjing, 2100008
Research Site
Nanjing, 210029
Research Site
Qingdao, 266003
Research Site
Shanghai, 200000
Research Site
Shanghai, 200001
Research Site
Shanghai, 200032
Research Site
Shanghai, 200080
Research Site
Shanghai, 200127
Research Site
Shanghai, CN-200092
Research Site
Taiyuan, 030001
Research Site
Tianjin, 300121
Research Site
Tianjin, CN-300052
Research Site
Wuhan, 430022
Research Site
Wuxi, 214023
Research Site
Xi'an, 710061

Other trials in China

Poland24 sites

Research Site
Bialystok, 15-111
Research Site
Bydgoszcz, 85-094
Research Site
Bydgoszcz, 85-231
Research Site
Gdynia, 81-157
Research Site
Gdynia, 81-402
Research Site
Gdynia, 81-423
Research Site
Gdynia, 81-472
Research Site
Grodzisk Mazowiecki, 05-825
Research Site
Katowice, 40-954
Research Site
Krakow, 30-529
Research Site
Krakow, 31-202
Research Site
Łęczna, 21-010
Research Site
Lodz, 90-338
Research Site
Lodz, 94-238
Research Site
Lublin, 20-044
Research Site
Ostrów Mazowiecka, 07-300
Research Site
Tarnów, 33-100
Research Site
Torun, 87-100
Research Site
Warsaw, 00-899
Research Site
Warsaw, 01-211
Research Site
Warsaw, 01-868
Research Site
Warsaw, 04-628
Research Site
Wroclaw, 51-124
Research Site
Zamość, 22-400

Other trials in Poland

Italy23 sites

Research Site
Ancona, 60122
Research Site
Avellino, 83100
Research Site
Castelfranco Veneto, 31033
Research Site
Catania, 95100
Research Site
Catania, 95124
Research Site
Chieti, 66013
Research Site
Genova, 16132
Research Site
Lecce, 7310
Research Site
Milan, 20138
Research Site
Milan, 20162
Research Site
Naples, 80100
Research Site
Naples, 80131
Research Site
Oristano, 09170
Research Site
Padova, 35128
Research Site
Palermo, 90135
Research Site
Perugia, 06156
Research Site
Piacenza, 29100
Research Site
Pisa, 56124
Research Site
Ragusa, 97100
Research Site
Reggio Emilia, 42100
Research Site
Roma, 00161
Research Site
San Giovanni Rotondo, 71013
Research Site
Siena, 53100

Other trials in Italy

Hungary21 sites

Research Site
Budapest, 1106
Research Site
Budapest, 1115
Research Site
Budapest, 1122
Research Site
Budapest, 1134
Research Site
Budapest, 1212
Research Site
Debrecen, 4025
Research Site
Debrecen, 4032
Research Site
Eger, 3300
Research Site
Gyöngyös, 3201
Research Site
Gyula, 5700
Research Site
Kaposvár, 7400
Research Site
Kecskemét, 6000
Research Site
Kistarcsa, 2143
Research Site
Miskolc, 3526
Research Site
Mosonmagyaróvár, 9200
Research Site
Nyíregyháza, 4400
Research Site
Pécs, 7624
Research Site
Szeged, 6721
Research Site
Székesfehérvár, 8000
Research Site
Szombathely, 9700
Research Site
Veszprém, 8200

Other trials in Hungary

Argentina18 sites

Research Site
Buenos Aires, 1078
Research Site
Buenos Aires, C1425AGC
Research Site
CABA, 1428
Research Site
CABA, C1119ACN
Research Site
CABA, C1179AAB
Research Site
Ciudadela, 1702
Research Site
Córdoba, 5000
Research Site
Córdoba, X5000AAW
Research Site
Córdoba, X5008HHW
Research Site
La Plata, 1900
Research Site
La Plata, B1902COS
Research Site
Mar del Plata, B7600GNY
Research Site
Rosario, 2000
Research Site
Rosario, S2000CXP
Research Site
Rosario, S2000DNM
Research Site
Rosario Santa Fe, S2000CVD
Research Site
San Nicolás, B2900DMH
Research Site
Santa Fe, S3000FWO

Other trials in Argentina

Bulgaria18 sites

Research Site
Burgas, 8127
Research Site
Gotse Delchev, 2900
Research Site
Haskovo, 6300
Research Site
Pleven, 5800
Research Site
Plovdiv, 4000
Research Site
Razlog, 2760
Research Site
Rousse, 7002
Research Site
Samokov, 2000
Research Site
Sandanski, 2800
Research Site
Sevlievo, 5400
Research Site
Sliven, 5000
Research Site
Sofia, 1000
Research Site
Sofia, 1142
Research Site
Sofia, 1233
Research Site
Sofia, 1309
Research Site
Sofia, 1407
Research Site
Sofia, 1606
Research Site
Sofia, 1784

Other trials in Bulgaria

Romania17 sites

Research Site
Bacau, 600114
Research Site
Brăila, 810249
Research Site
Brasov, 500283
Research Site
Bucharest, 011461
Research Site
Bucharest, 011601
Research Site
Bucharest, 061118
Research Site
Buzău, 120203
Research Site
Cluj-Napoca, 400001
Research Site
Craiova, 200147
Research Site
Craiova, 200642
Research Site
Iași, 700304
Research Site
Piteşti, 110084
Research Site
Sibiu, 550245
Research Site
Sibiu, 550371
Research Site
Suceava, 720284
Research Site
Tg. Mures, 540124
Research Site
Timișoara, 300359

Other trials in Romania

Czechia15 sites

Research Site
Brno, 602 00
Research Site
Brno, 656 91
Research Site
Chomutov, 430 02
Research Site
Hodonín, 695 01
Research Site
Hradec Králové, 500 05
Research Site
Jindřichův Hradec, 377 01
Research Site
Kladno, 272 59
Research Site
Liberec, 460 63
Research Site
Olomouc, 775 20
Research Site
Ostrava-Dubina, 700 30
Research Site
Prague, 101 00
Research Site
Prague, 108 00
Research Site
Prague, 110 00
Research Site
Prague, 128 08
Research Site
Slaný, 274 01

Other trials in Czechia

Philippines15 sites

Research Site
Cebu, 6000
Research Site
Cebu City, 6000
Research Site
City of Taguig, 1634
Research Site
Dasmariñas, 4114
Research Site
Iloilo City, 5000
Research Site
Lipa City, 4217
Research Site
Makati, 1229
Research Site
Mandaluyong, 1554
Research Site
Manila, 1015
Research Site
Manila, 2043
Research Site
Pasig, 1600
Research Site
Quezon City, 1100
Research Site
Quezon City, 1102
Research Site
Tanauan, 4232
Research Site
Vigan, 2700

Other trials in Philippines

Ukraine15 sites

Research Site
Ivano-Frankivsk, 76000
Research Site
Ivano-Frankivsk, 76012
Research Site
Kharkiv, 61039
Research Site
Kharkiv, 61103
Research Site
Kharkiv, 61178
Research Site
Kyiv, 01601
Research Site
Kyiv, 02176
Research Site
Kyiv, 03000
Research Site
Odesa, 65025
Research Site
Uzhhorod, 88009
Research Site
Vinnytsia, 21018
Research Site
Zaporizhzhya, 69032
Research Site
Zaporizhzhya, 69104
Research Site
Zaporizhzhya, 69118
Research Site
Zaporizhzhya, 69600

Other trials in Ukraine

Mexico14 sites

Research Site
Aguascalientes, 20230
Research Site
Chihuahua City, 31203
Research Site
Culiacán, 80230
Research Site
Guadalajara, 44670
Research Site
Guadalajara, 44676
Research Site
México, 14000
Research Site
México, 6700
Research Site
Monclova, 25750
Research Site
Monterrey, 64060
Research Site
Monterrey, 64460
Research Site
Querétaro, 76000
Research Site
San Luis Potosí City, 78200
Research Site
San Luis Potosí City, 78240
Research Site
Tijuana, 22014

Other trials in Mexico

South Korea14 sites

Research Site
Bucheon-si, 14754
Research Site
Busan, 49241
Research Site
Cheonan-si, 330-715
Research Site
Daegu, 700-712
Research Site
Daejeon, 301-721
Research Site
Incheon, 405-760
Research Site
Seongnam-si, 13620
Research Site
Seoul, 03722
Research Site
Seoul, 05505
Research Site
Seoul, 06591
Research Site
Seoul, 08308
Research Site
Seoul, 130-872
Research Site
Seoul, 135-710
Research Site
Seoul, 156-707

Other trials in South Korea

Turkey (Türkiye)12 sites

Research Site
Ankara, 06100
Research Site
Ankara, 06490
Research Site
Ankara, 06800
Research Site
Bursa, 16059
Research Site
Bursa, 16330
Research Site
Istanbul, 34096
Research Site
Istanbul, 34303
Research Site
Istanbul, 34668
Research Site
Istanbul, 34846
Research Site
Izmir, 35100
Research Site
Izmir, 35360
Research Site
Malatya, 44280

Other trials in Turkey (Türkiye)

United Kingdom12 sites

Research Site
Aberdeen, AB25 2ZN
Research Site
Birmingham, B91 2LJ
Research Site
Bournemouth, BH7 7DW
Research Site
Cambridge, CB2 0QQ
Research Site
Cheltenham, GL53 7AN
Research Site
Dundee, DD1 9SY
Research Site
Hull, HU3 2JZ
Research Site
Leeds, LS1 3EX
Research Site
Leicester, LE1 5WW
Research Site
London, SW17 0QT
Research Site
Newcastle upon Tyne, NE7 7DN
Research Site
Worcester, WR5 1DD

Other trials in United Kingdom

Chile10 sites

Research Site
Concepción, 4070060
Research Site
Santiago, 7500520
Research Site
Santiago, 7500710
Research Site
Santiago, 8207257
Research Site
Santiago, 8330024
Research Site
Santiago, 8380456
Research Site
Talcahuano, 4260000
Research Site
Temuco, 4781173
Research Site
Temuco, 4810371
Research Site
Viña del Mar, 2520997

Other trials in Chile

Netherlands10 sites

Research Site
Amsterdam, 1066 EC
Research Site
Capelle aan den IJssel, 2906 ZC
Research Site
Eindhoven, 5623 EJ
Research Site
Eindhoven, 5631 BM
Research Site
Groningen, 9713 GZ
Research Site
Heerlen, 6419 PC
Research Site
Leiden, 2333 ZA
Research Site
Nijmegen, 6532 SZ
Research Site
Rotterdam, 3045 PM
Research Site
Utrecht, 3584 CX

Other trials in Netherlands

Sweden10 sites

Research Site
Eksjö, 575 81
Research Site
Gävle, 801 87
Research Site
Gothenburg, 413 45
Research Site
Karlstad, 651 85
Research Site
Malmö, 205 02
Research Site
Örebro, 701 85
Research Site
Stockholm, 118 83
Research Site
Stockholm, 171 76
Research Site
Uppsala, 751 85
Research Site
Västerås, 721 89

Other trials in Sweden

Slovakia8 sites

Research Site
Dunajská Streda, 929 01
Research Site
Košice, 040 01
Research Site
Nitra, 949 01
Research Site
Nové Zámky, 940 72
Research Site
Poprad, 058 49
Research Site
Prešov, 080 01
Research Site
Trnava, 917 01
Research Site
Žilina, 010 01

Other trials in Slovakia

Thailand5 sites

Research Site
Bangkok, 10330
Research Site
Bangkok, 10400
Research Site
Bangkoknoi, 10700
Research Site
Muang, 40002
Research Site
Songkhla, 90110

Other trials in Thailand

Vietnam4 sites

Research Site
Hanoi
Research Site
Ho Chi Minh City, 700000
Research Site
Ho Chi Minh City
Research Site
Hochiminh

Other trials in Vietnam

About this study

Official title: A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.

Read the detailed description

A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Conditions: Peripheral Artery Disease
Being tested: Ticagrelor, Clopidogrel
Keywords: Peripheral artery disease Atherothrombotic events Atherosclerosis
Medical subject headings: Peripheral Arterial Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

TicagrelorDrug
Also called Brilinta/Brilique
Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
ClopidogrelDrug
Also called Plavix
Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets

Study groups in NCT01732822
Study group	Role	What they receive
Ticagrelor	Experimental	Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets Receives: Drug: Ticagrelor
Clopidogrel	Active comparator	Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets Receives: Drug: Clopidogrel

What is being measured

The primary outcome is the main question the study is designed to answer.

Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date)
Measured: From randomization to PACD, an average of 2.5 years

Secondary outcomes (8)

Composite of CV Death, MI, Ischemic Stroke, and ALI
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Measured: From randomization to PACD, an average of 2.5 years
CV Death
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Measured: From randomization to PACD, an average of 2.5 years
MI
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Measured: From randomization to PACD, an average of 2.5 years
All-cause Mortality
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
Measured: From randomization to PACD, an average of 2.5 years
Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Measured: From randomization to PACD, an average of 2.5 years
ALI
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Measured: From randomization to PACD, an average of 2.5 years
Lower Extremity Revascularization
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Measured: From randomization to PACD, an average of 2.5 years
Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Measured: From randomization to PACD, an average of 2.5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

4 Dec 201226 Sep 2016

First posted26 Nov 2012 (estimated)
Study start4 Dec 2012
Primary completion26 Sep 2016
Study completion26 Sep 2016

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (23)Papers the sponsor has linked to this study.
Other trials for Peripheral Artery DiseaseStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Prevention
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 13,885 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01732822
Sponsor's protocol ID: D5135C00001
Other IDs: 2011-004616-36
Acronym: EUCLID
Status last verified: Sep 2017
First submitted: 20 Nov 2012
Last updated: 30 Oct 2017
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes

Publications

Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, Katona B, Mahaffey KW, Norgren L, Blomster J, Rockhold FW, Hsia J, Fowkes FGR, Bonaca MP. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. J Am Heart Assoc. 2022 Jun 7;11(11):e025504. doi: 10.1161/JAHA.122.025504. Epub 2022 May 27.
PubMed 35621222
Govsyeyev N, Nehler MR, Low Wang CC, Kavanagh S, Hiatt WR, Long C, Jones WS, Fowkes FGR, Berger JS, Baumgartner I, Patel MR, Goodney PP, Beckman JA, Katona BG, Mahaffey KW, Blomster J, Norgren L, Bonaca MP. Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. J Vasc Surg. 2022 Feb;75(2):660-670.e3. doi: 10.1016/j.jvs.2021.08.096. Epub 2021 Sep 28.
PubMed 34597783
Norgren L, North R, Baumgartner I, Berger JS, Blomster JI, Hiatt WR, Jones WS, Katona BG, Mahaffey KW, Mulder H, Patel MR, Rockhold FW, Fowkes FGR. World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. Vasc Med. 2022 Feb;27(1):21-29. doi: 10.1177/1358863X211038620. Epub 2021 Sep 13.
PubMed 34516308
Hiatt WR, Hess CN, Bonaca MP, Kavanagh S, Patel MR, Baumgartner I, Berger JS, Blomster JI, Jones WS, Katona BG, Mahaffey KW, Norgren L, Rockhold FW, Fowkes FGR. Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circ Cardiovasc Interv. 2021 Jul;14(7):e009871. doi: 10.1161/CIRCINTERVENTIONS.120.009871. Epub 2021 Jul 13.
PubMed 34253048
Hsia J, Kavanagh ST, Hopley CW, Baumgartner I, Berger JS, Fowkes GR, Jones WS, Mahaffey KW, Norgren L, Patel MR, Rockhold F, Blomster J, Katona BG, Hiatt WR, Bonaca MP. Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vasc Med. 2021 Dec;26(6):608-612. doi: 10.1177/1358863X211017641. Epub 2021 Jun 3.
PubMed 34082620
Galani J, Mulder H, Rockhold FW, Weissler EH, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Hiatt WR, Katona BG, Norgren L, Mahaffey KW, Quint JK, Patel MR, Jones WS. Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. Int J Chron Obstruct Pulmon Dis. 2021 Mar 29;16:841-851. doi: 10.2147/COPD.S292978. eCollection 2021.
PubMed 33824584
Kochar A, Mulder H, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Lopes RD, Al-Khalidi HR, Mahaffey KW, Norgren L, Hiatt WR, Patel MR, Jones WS. Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 Nov;13(11):e006550. doi: 10.1161/CIRCOUTCOMES.120.006550. Epub 2020 Nov 12.
PubMed 33176462
Gutierrez JA, Heizer GM, Jones WS, Rockhold FW, Mahaffey KW, Fowkes FGR, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster JI, Hiatt WR, Patel MR. CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. Am Heart J. 2020 Nov;229:118-120. doi: 10.1016/j.ahj.2020.07.017. Epub 2020 Aug 16. No abstract available.
PubMed 32950849
Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Ostrom C, Patel MR, Jones WS, Hiatt WR. Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 Sep;13(9):e006512. doi: 10.1161/CIRCOUTCOMES.120.006512. Epub 2020 Aug 31.
PubMed 32862697
Long CA, Mulder H, Fowkes FGR, Baumgartner I, Berger JS, Katona BG, Mahaffey KW, Norgren L, Blomster JI, Rockhold FW, Hiatt WR, Patel MR, Jones WS, Nehler MR. Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 Jul;13(7):e006399. doi: 10.1161/CIRCOUTCOMES.119.006399. Epub 2020 Jul 3.
PubMed 32615798
Haine A, Kavanagh S, Berger JS, Hess CN, Norgren L, Fowkes FGR, Katona BG, Mahaffey KW, Blomster JI, Patel MR, Jones WS, Rockhold FW, Hiatt WR, Baumgartner I; International Steering Committee and Investigators of the EUCLID Trial. Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. J Am Coll Cardiol. 2020 Feb 18;75(6):608-617. doi: 10.1016/j.jacc.2019.11.057.
PubMed 32057375
Ward R, Huang Z, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Vemulapalli S, Povsic TJ, Mehta R, Hiatt WR, Patel MR, Jones WS. Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. Am Heart J. 2020 Feb;220:51-58. doi: 10.1016/j.ahj.2019.11.007. Epub 2019 Nov 18.
PubMed 31783279
Hopley CW, Kavanagh S, Patel MR, Ostrom C, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Jones WS, Katona BG, Mahaffey KW, Norgren L, Rockhold FW, Hiatt WR. Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. Vasc Med. 2019 Oct;24(5):422-430. doi: 10.1177/1358863X19864172. Epub 2019 Jul 24.
PubMed 31339474
Hess CN, Huang Z, Patel MR, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Held P, Jones WS, Katona B, Mahaffey KW, Norgren L, Rockhold FW, Hiatt WR. Acute Limb Ischemia in Peripheral Artery Disease. Circulation. 2019 Aug 13;140(7):556-565. doi: 10.1161/CIRCULATIONAHA.119.039773. Epub 2019 Jun 26.
PubMed 31238713
Kolls BJ, Sapp S, Rockhold FW, Jordan JD, Dombrowski KE, Fowkes FGR, Mahaffey KW, Berger JS, Katona BG, Blomster JI, Norgren L, Abramson BL, Leiva-Pons JL, Prieto JC, Sokurenko G, Hiatt WR, Jones WS, Patel MR. Stroke in Patients With Peripheral Artery Disease. Stroke. 2019 Jun;50(6):1356-1363. doi: 10.1161/STROKEAHA.118.023534. Epub 2019 May 16.
PubMed 31092165

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Not yet recruiting
Daily Stretching to Improve Walking in Older Patients With Peripheral Artery Disease: The STRETCH PAD Study
Peripheral Artery Disease (PAD), Intermittent Claudication
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)

All Peripheral Artery Disease trials

Study at a glance

From the registry record, last updated by the sponsor on 30 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
ClinicalTrials.gov ID: NCT01732822
Acronym / sponsor ID: EUCLID / D5135C00001
Conditions: Peripheral Artery Disease
Keywords: Peripheral artery disease Atherothrombotic events Atherosclerosis
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 13,885 participants (actual)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 4 Dec 2012 (actual)
Primary completion: 26 Sep 2016 (actual)
Study completion: 26 Sep 2016 (actual)
First posted: 26 Nov 2012 (estimated)
Results: Posted 30 Oct 2017

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.

Detailed description

Study design

Primary purpose: Prevention
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2

Arm	Type	Receives
Ticagrelor	Experimental	Drug: TicagrelorTicagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
Clopidogrel	Active comparator	Drug: ClopidogrelClopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets

Who may qualify

Ages: 50 to 130 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (1 listed)

Male and Female patients 50 years old or older Symptomatic peripheral artery disease

Key exclusion criteria (4 listed)

Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation
Patients with known bleeding disorders
Patients with a history of intracranial bleed
Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
TicagrelorAlso: Brilinta/BriliqueTicagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets	Drug	Ticagrelor
ClopidogrelAlso: PlavixClopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets	Drug	Clopidogrel

Primary outcome

Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke
Time frame: From randomization to PACD, an average of 2.5 years
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date)

8 secondary outcomes

Composite of CV Death, MI, Ischemic Stroke, and ALI
Time frame: From randomization to PACD, an average of 2.5 years
CV Death
Time frame: From randomization to PACD, an average of 2.5 years
MI
Time frame: From randomization to PACD, an average of 2.5 years
All-cause Mortality
Time frame: From randomization to PACD, an average of 2.5 years
Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)
Time frame: From randomization to PACD, an average of 2.5 years
ALI
Time frame: From randomization to PACD, an average of 2.5 years
Lower Extremity Revascularization
Time frame: From randomization to PACD, an average of 2.5 years
Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])
Time frame: From randomization to PACD, an average of 2.5 years

Results and safety

Results posted to the registry on 30 Oct 2017, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Ticagrelor 90 mg bd	6,930	6,807
Clopidogrel 75 mg od	6,955	6,842

Primary outcome: Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke

Time frame: From randomization to PACD, an average of 2.5 years. Number. Unit: Participants

Measure	Ticagrelor 90 mg bd n = 6930	Clopidogrel 75 mg od n = 6955
Value	751	740

Ticagrelor 90 mg bd vs Clopidogrel 75 mg od: Hazard Ratio (HR): 1.02 (95% CI 0.92 to 1.13), p = 0.650, Regression, Cox

Population analysed: The population was the full analysis set, which included all randomized patients.

8 secondary outcomes are reported in the full results.

Adverse events

Time frame: On or after the date of first dose and up to and including 7 days following the date of last dose of study medication. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Clopidogrel 75mg od	1,788 of 6,932 (25.8%)	989 of 6,932 (14.3%)	Not reported
Ticagrelor 90mg bd	1,716 of 6,910 (24.8%)	1,682 of 6,910 (24.3%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2017.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 35621222Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, Katona B, Mahaffey KW, Norgren L, Blomster J, Rockhold FW, Hsia J, Fowkes FGR, Bonaca MP. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. J Am Heart Assoc. 2022 Jun 7;11(11):e025504. doi: 10.1161/JAHA.122.025504. Epub 2022 May 27.
Derived from this study: PubMed 34597783Govsyeyev N, Nehler MR, Low Wang CC, Kavanagh S, Hiatt WR, Long C, Jones WS, Fowkes FGR, Berger JS, Baumgartner I, Patel MR, Goodney PP, Beckman JA, Katona BG, Mahaffey KW, Blomster J, Norgren L, Bonaca MP. Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. J Vasc Surg. 2022 Feb;75(2):660-670.e3. doi: 10.1016/j.jvs.2021.08.096. Epub 2021 Sep 28.
Derived from this study: PubMed 34516308Norgren L, North R, Baumgartner I, Berger JS, Blomster JI, Hiatt WR, Jones WS, Katona BG, Mahaffey KW, Mulder H, Patel MR, Rockhold FW, Fowkes FGR. World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. Vasc Med. 2022 Feb;27(1):21-29. doi: 10.1177/1358863X211038620. Epub 2021 Sep 13.
Derived from this study: PubMed 34253048Hiatt WR, Hess CN, Bonaca MP, Kavanagh S, Patel MR, Baumgartner I, Berger JS, Blomster JI, Jones WS, Katona BG, Mahaffey KW, Norgren L, Rockhold FW, Fowkes FGR. Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circ Cardiovasc Interv. 2021 Jul;14(7):e009871. doi: 10.1161/CIRCINTERVENTIONS.120.009871. Epub 2021 Jul 13.
Derived from this study: PubMed 34082620Hsia J, Kavanagh ST, Hopley CW, Baumgartner I, Berger JS, Fowkes GR, Jones WS, Mahaffey KW, Norgren L, Patel MR, Rockhold F, Blomster J, Katona BG, Hiatt WR, Bonaca MP. Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vasc Med. 2021 Dec;26(6):608-612. doi: 10.1177/1358863X211017641. Epub 2021 Jun 3.
Derived from this study: PubMed 33824584Galani J, Mulder H, Rockhold FW, Weissler EH, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Hiatt WR, Katona BG, Norgren L, Mahaffey KW, Quint JK, Patel MR, Jones WS. Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. Int J Chron Obstruct Pulmon Dis. 2021 Mar 29;16:841-851. doi: 10.2147/COPD.S292978. eCollection 2021.
Derived from this study: PubMed 33176462Kochar A, Mulder H, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Lopes RD, Al-Khalidi HR, Mahaffey KW, Norgren L, Hiatt WR, Patel MR, Jones WS. Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 Nov;13(11):e006550. doi: 10.1161/CIRCOUTCOMES.120.006550. Epub 2020 Nov 12.
Derived from this study: PubMed 32950849Gutierrez JA, Heizer GM, Jones WS, Rockhold FW, Mahaffey KW, Fowkes FGR, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster JI, Hiatt WR, Patel MR. CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. Am Heart J. 2020 Nov;229:118-120. doi: 10.1016/j.ahj.2020.07.017. Epub 2020 Aug 16. No abstract available.
Derived from this study: PubMed 32862697Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Ostrom C, Patel MR, Jones WS, Hiatt WR. Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 Sep;13(9):e006512. doi: 10.1161/CIRCOUTCOMES.120.006512. Epub 2020 Aug 31.
Derived from this study: PubMed 32615798Long CA, Mulder H, Fowkes FGR, Baumgartner I, Berger JS, Katona BG, Mahaffey KW, Norgren L, Blomster JI, Rockhold FW, Hiatt WR, Patel MR, Jones WS, Nehler MR. Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 Jul;13(7):e006399. doi: 10.1161/CIRCOUTCOMES.119.006399. Epub 2020 Jul 3.
Derived from this study: PubMed 32057375Haine A, Kavanagh S, Berger JS, Hess CN, Norgren L, Fowkes FGR, Katona BG, Mahaffey KW, Blomster JI, Patel MR, Jones WS, Rockhold FW, Hiatt WR, Baumgartner I; International Steering Committee and Investigators of the EUCLID Trial. Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. J Am Coll Cardiol. 2020 Feb 18;75(6):608-617. doi: 10.1016/j.jacc.2019.11.057.
Derived from this study: PubMed 31783279Ward R, Huang Z, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Vemulapalli S, Povsic TJ, Mehta R, Hiatt WR, Patel MR, Jones WS. Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. Am Heart J. 2020 Feb;220:51-58. doi: 10.1016/j.ahj.2019.11.007. Epub 2019 Nov 18.
Redacted ProtocolLink provided by the sponsor.

Related trials for Peripheral Artery Disease

Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Not yet recruiting
Daily Stretching to Improve Walking in Older Patients With Peripheral Artery Disease: The STRETCH PAD Study
Peripheral Artery Disease (PAD), Intermittent Claudication
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

William R Hiatt, MD study chair

University of Colorado School of Medicine

Peter Held, MD study director

AstraZeneca

776 sites in 28 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Ticagrelor and Clopidogrel in people with Peripheral Artery Disease, run by AstraZeneca at 776 sites in 28 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 776 sites in United States, Japan, Russia, Spain, Canada and 23 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Oct 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke (time frame: From randomization to PACD, an average of 2.5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01732822, which also lists 23 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2017.